Implandata Announces Closing of €3M Series B-Round, Establishment of Fully Owned USA Subsidiary and Progress in Clinical Program

Implandata logo

Hannover, Germany, October 27, 2014 / B3C newswire / -  Implandata Ophthalmic Products GmbH (Implandata) an ophthalmic surgical product and e-Health start-up company announces the closing of a €3M Series B-Round. Born2Grow Venture Partners, a private fund based in Heilbronn/Germany joins in as new investor. Previous investors Peppermint Charité Beteiligungsfonds/Berlin, Hannover Beteiligungsfonds/Hannover, High-Tech Gründerfonds/Bonn, KfW/Bonn and a group of Business Angels complete the Series B funding round.

With the proceeds of this funding, the company is enabled to complete the  clinical program for CE marking of its first product, to launch further studies for complementary product lines and applications in Germany and abroad, specifically to initiate the first IDE study with Massachusetts Eye and Ear Infirmary, Boston/MA and Kellogg Eye Institute, Ann Arbor/MI. For this purpose and in order to prepare the commercial launch of Implandata’s products in the USA, the company established fully owned US subsidiary Implandata Ophthalmic Products, Inc., located in Wilmington/DE. In very near future the company will start further clinical studies for expansion of product use, for clinical validation of complementary product versions and for integrating its pressure sensing technology platform into other ophthalmic surgical procedures and products.

Implandata is currently conducting multi-centric ARGOS-02 study with its intraocular pressure sensor for continuous monitoring of glaucoma patients eye pressure. During cataract surgery Implandata’s pressure sensing implant is placed in front of the artificial intraocular lens, posterior to the iris. After implantation of the micro sensor the patient’s intraocular pressure can be measured at any chosen frequency, either continuously over the course of 24 hours or on demand at defined time points. Patients can perform measurements by themselves and under normal live conditions. Collected data will be sent via a mobile phone module to the eye doctor’s computer screen, allowing remotely monitoring and managing the patient’s disease and alerting the eye doctor in case of patients uncontrolled intraocular pressure.

Implandata’s intraocular pressure sensor allows close monitoring of the patients disease progression and glaucoma therapy success. Through simple and more frequent measurements of intraocular pressure - which is the key parameter in glaucoma therapy - important information on therapy response is delivered to the eye doctor early on, enabling immediate glaucoma therapy adjustment, contributing to prevention of further vision loss due to uncontrolled intraocular pressure.


About
 Implandata Ophthalmic Products GmbH
Implandata Ophthalmic Products GmbH is a privately held medical device company founded in 2010, headquartered in Hannover, Germany, since 2014 with a fully owned US subsidiary in Wilmington/DE. Implandata’s product for continuous monitoring of intraocular pressure and e-Health integration will transform management of glaucoma patients, providing dramatically improved quality and quantity of intraocular pressure data, which is key for personalized care and therapy control. Remote patient management will increase glaucoma treatment efficiency and results in cost savings for all stakeholders.


Contact

Max G. Ostermeier
Implandata Ophthalmic Products GmbH
Kokenstrasse 5
30159 Hannover
Phone: +49 511 2204 2581
Fax: +49 511 2204 2589
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok